<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023047</url>
  </required_header>
  <id_info>
    <org_study_id>RDD 112</org_study_id>
    <nct_id>NCT02023047</nct_id>
  </id_info>
  <brief_title>An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing</brief_title>
  <official_title>An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDD Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDD Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study. The study will consist of 2 treatment group: coated Nifedipine&#xD;
      suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated&#xD;
      Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).&#xD;
      Approximately 30 subjects will participate into this 8-week study. The primary objective is&#xD;
      to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and healing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study. The study will consist of 2 treatment group: coated Nifedipine&#xD;
      suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated&#xD;
      Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).&#xD;
      Approximately 30 subjects will participate into this 8-week study. A screening visit will be&#xD;
      used to determine subject suitability for inclusion in the trial. Within one week of the&#xD;
      screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria&#xD;
      will receive Coated Nifedipine 12 mg Suppository X2 a day (BID) (24 mg/day total) OR Coated&#xD;
      Nifedipine 12 mg Suppository X1 a day (OD) (12 mg/day total) for a period of 8 weeks. During&#xD;
      this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication will&#xD;
      be administered BID (in the morning and in the evening) or OD (only in the morning). In&#xD;
      addition to receiving study medication, subjects will be maintained on a standard treatment&#xD;
      for Anal Fissure: sitz baths, high fiber diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Met primary endpoint&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score</measure>
    <time_frame>8 weeks after study initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients .</measure>
    <time_frame>8 weeks</time_frame>
    <description>safety will be assessed by the number of participants with adverse events. Tolerability will be assessed by the number of participants that discontinue treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Anal Fissure</condition>
  <arm_group>
    <arm_group_label>Once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine 12 mg Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine 12 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine 12 mg coated suppositories</intervention_name>
    <arm_group_label>Once daily</arm_group_label>
    <arm_group_label>Twice Daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single anal fissure&#xD;
&#xD;
          -  Signed written informed consent;&#xD;
&#xD;
          -  Male or female subjects 18 to 65 years of age;&#xD;
&#xD;
          -  Has chronic anal fissure defined as history of anal pain at least three days a week&#xD;
             for 30 days duration or more&#xD;
&#xD;
          -  Visible fibers of the internal sphincter were seen at the base of the fissure or if a&#xD;
             sentinel pile was present.&#xD;
&#xD;
          -  VAS of &gt; 35 mm in screening visit&#xD;
&#xD;
          -  If female, is non-lactating, has a negative urine pregnancy test result, and does not&#xD;
             plan on becoming pregnant during the study, or not of childbearing potential&#xD;
             (hysterectomy or tubal ligation at least 6 months prior to entry to the study or&#xD;
             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal&#xD;
             women who have had a menstrual period within one year) must practice or be willing to&#xD;
             continue to practice appropriate birth control (such as implants, injectables, oral&#xD;
             contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal&#xD;
             ligation, or a vasectomized partner) during the entire study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone.&#xD;
&#xD;
          -  Fissure resulting from inflammatory bowel disease, venereal disease, perianal&#xD;
             psoriasis, immunodeficiency syndrome.&#xD;
&#xD;
          -  Anal abscess&#xD;
&#xD;
          -  Fixed anal stenosis&#xD;
&#xD;
          -  Active or past history of cardiovascular or cerebrovascular disease including unstable&#xD;
             angina, myocardial infarction, transient ischemic attacks/stroke, clinically&#xD;
             significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve&#xD;
             abnormalities;&#xD;
&#xD;
          -  Type 1 diabetes mellitus;&#xD;
&#xD;
          -  Insulin treated type 2 diabetes mellitus;&#xD;
&#xD;
          -  History of Renal insufficiency.&#xD;
&#xD;
          -  History of Liver insufficiency.&#xD;
&#xD;
          -  Malignant disease within 5 years of screening;&#xD;
&#xD;
          -  Has uncontrolled hypertension (sitting blood pressure &lt;160/95 mmHg at screening)&#xD;
&#xD;
          -  History of chronic gastrointestinal disease.&#xD;
&#xD;
          -  History of rectal surgery.&#xD;
&#xD;
          -  History of gastrointestinal surgery.&#xD;
&#xD;
          -  History of HIV, hepatitis B, hepatitis C.&#xD;
&#xD;
          -  In need of chronic use of medication, with the exception of birth control medications.&#xD;
&#xD;
          -  Currently uses medication for acute illness (other than medications for use of&#xD;
             treatment/pain relief of anal fissure).&#xD;
&#xD;
          -  Has used, in the last two weeks, drugs that may affect blood coagulation, such as&#xD;
             Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin,&#xD;
             Heparin, Clopidogrel, Ticlopidine.&#xD;
&#xD;
          -  Is using drug that may affect rectal tone:&#xD;
&#xD;
          -  Calcium Channel Blocker such as:&#xD;
&#xD;
               -  Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)&#xD;
&#xD;
               -  Amlodipine (Amlow, Norvasc, Amlodipine-Teva)&#xD;
&#xD;
               -  Lercadipine (Vasodip)&#xD;
&#xD;
               -  Verapamil (Ikacor, Ikapress, Verapress)&#xD;
&#xD;
               -  Felodipine (Penedil)&#xD;
&#xD;
               -  Diltiazem (Adizem, Dilatam)&#xD;
&#xD;
          -  Nitrate donors such as:&#xD;
&#xD;
               -  Glyceryl Trinitrate (Deponit)&#xD;
&#xD;
               -  Isosorbid dinitrate (Isoket, Isolong)&#xD;
&#xD;
               -  Isosrbid mononitrate (Monocord, Monolong, Mononit)&#xD;
&#xD;
               -  Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual)&#xD;
&#xD;
          -  Has upon physical examination a rectal deformation or signs of rectal disease such as&#xD;
             bleeding hemorrhoids, fistula. infection or space occupying lesion.&#xD;
&#xD;
          -  Is an immediate family member of personnel directly affiliated with the study at the&#xD;
             investigative site, or is personally directly affiliated with the study at the&#xD;
             investigative site; or&#xD;
&#xD;
          -  Is employed by RDD Pharma Ltd.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nir Barak, MD</last_name>
    <role>Study Director</role>
    <affiliation>RDD Pharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Macabi outpatient clinic</name>
      <address>
        <city>Beer Sheba</city>
        <state>Negev</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macabi outpatient clinic</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macabi HMO outpatient clinic</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Hospital</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <last_update_submitted>November 15, 2015</last_update_submitted>
  <last_update_submitted_qc>November 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anal Fissure</keyword>
  <keyword>Nifedipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

